Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice

BACKGROUND: The use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) could affect COVID-19 outcomes by modulating the immune response, which, in turn, might favor viral replication and/or confer protection from COVID-19 induced inflammatory response CASE REPORT: We report on two MS p...

Descripción completa

Detalles Bibliográficos
Autores principales: De Angelis, Marcello, Petracca, Maria, Lanzillo, Roberta, Brescia Morra, Vincenzo, Moccia, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428688/
https://www.ncbi.nlm.nih.gov/pubmed/32823148
http://dx.doi.org/10.1016/j.msard.2020.102452
_version_ 1783571130409287680
author De Angelis, Marcello
Petracca, Maria
Lanzillo, Roberta
Brescia Morra, Vincenzo
Moccia, Marcello
author_facet De Angelis, Marcello
Petracca, Maria
Lanzillo, Roberta
Brescia Morra, Vincenzo
Moccia, Marcello
author_sort De Angelis, Marcello
collection PubMed
description BACKGROUND: The use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) could affect COVID-19 outcomes by modulating the immune response, which, in turn, might favor viral replication and/or confer protection from COVID-19 induced inflammatory response CASE REPORT: We report on two MS patients treated with cladribine, with heterogeneous demographics and clinical features, who developed mild or no symptoms from COVID-19 and produced anti-SARS-CoV-2 antibodies, notwithstanding low lymphocyte levels. IMPLICATIONS: Benign COVID-19 clinical course and anti-SARS-CoV-2 antibody production can occur in MS patients with lymphopenia, suggesting the possibility to respond to COVID-19 vaccination, once available, in this vulnerable population.
format Online
Article
Text
id pubmed-7428688
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-74286882020-08-17 Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice De Angelis, Marcello Petracca, Maria Lanzillo, Roberta Brescia Morra, Vincenzo Moccia, Marcello Mult Scler Relat Disord Correspondence BACKGROUND: The use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) could affect COVID-19 outcomes by modulating the immune response, which, in turn, might favor viral replication and/or confer protection from COVID-19 induced inflammatory response CASE REPORT: We report on two MS patients treated with cladribine, with heterogeneous demographics and clinical features, who developed mild or no symptoms from COVID-19 and produced anti-SARS-CoV-2 antibodies, notwithstanding low lymphocyte levels. IMPLICATIONS: Benign COVID-19 clinical course and anti-SARS-CoV-2 antibody production can occur in MS patients with lymphopenia, suggesting the possibility to respond to COVID-19 vaccination, once available, in this vulnerable population. Elsevier B.V. 2020-10 2020-08-16 /pmc/articles/PMC7428688/ /pubmed/32823148 http://dx.doi.org/10.1016/j.msard.2020.102452 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
De Angelis, Marcello
Petracca, Maria
Lanzillo, Roberta
Brescia Morra, Vincenzo
Moccia, Marcello
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
title Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
title_full Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
title_fullStr Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
title_full_unstemmed Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
title_short Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
title_sort mild or no covid-19 symptoms in cladribine-treated multiple sclerosis: two cases and implications for clinical practice
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428688/
https://www.ncbi.nlm.nih.gov/pubmed/32823148
http://dx.doi.org/10.1016/j.msard.2020.102452
work_keys_str_mv AT deangelismarcello mildornocovid19symptomsincladribinetreatedmultiplesclerosistwocasesandimplicationsforclinicalpractice
AT petraccamaria mildornocovid19symptomsincladribinetreatedmultiplesclerosistwocasesandimplicationsforclinicalpractice
AT lanzilloroberta mildornocovid19symptomsincladribinetreatedmultiplesclerosistwocasesandimplicationsforclinicalpractice
AT bresciamorravincenzo mildornocovid19symptomsincladribinetreatedmultiplesclerosistwocasesandimplicationsforclinicalpractice
AT mocciamarcello mildornocovid19symptomsincladribinetreatedmultiplesclerosistwocasesandimplicationsforclinicalpractice

Ejemplares similares